Zylox-Tonbridge and GL Capital Team Up to Transform Heart Interventions in China

A New Era for Heart Interventions in China

In a significant move poised to revolutionize medical technology in the vascular and structural heart segments, Zylox-Tonbridge Medical Technology Co., Ltd. has announced a joint investment with GL Capital into LifeTech Scientific Corporation. This strategic collaboration aims to integrate two companies' strengths, enhancing innovation and expanding their influence in the Chinese healthcare sector.

Uniting Strengths for Comprehensive Solutions

Zylox-Tonbridge, listed on the Hong Kong Stock Exchange as HKEX: 2190, is known for its work in peripheral vascular and neurovascular interventions. LifeTech, another listed entity (HKEX: 1302), specializes in developing minimally invasive interventional medical devices, particularly in cardio-cerebrovascular and peripheral vascular diseases. The merger of their technological capabilities is set to create a comprehensive vascular and structural heart intervention platform, catering to the growing needs of patients across China.

This partnership emerges at a critical time when the demand for advanced medical technology is escalating, driven by an increasing prevalence of cardiovascular diseases. By pooling resources and expertise, Zylox-Tonbridge and LifeTech can create a powerful portfolio that encompasses four major therapeutic areas. This integration not only stands to benefit both companies but also enhances the overall landscape of healthcare solutions available to patients.

Investment Details: A Significant Financial Commitment

The partnership has designed a robust financial framework for the proposed collaboration. Zylox-Tonbridge, alongside GL Capital through GL Lighthouse Two Investment Limited, plans to invest approximately HK$1.482 billion. This substantial investment will secure around 16.7% of LifeTech's expanded share capital, making it the largest single shareholder post-transaction. Furthermore, Zylox-Tonbridge intends to hold a 60% stake in Lighthouse Two after an investment influx of about HK$889 million, highlighting the financial confidence in LifeTech's capabilities and market potential.

In tandem, GL Capital has committed to acquiring nearly 40 million shares in Zylox-Tonbridge, further strengthening ties between the organizations. This financial backing underscores GL Capital's enduring faith in the growing healthcare sector within China and its willingness to invest in companies demonstrating competitive potential.

Strengthening International Presence

Both Zylox-Tonbridge and LifeTech boast robust international networks, strategically positioning them to seize opportunities in global markets. Zylox-Tonbridge reported an extraordinary 349.3% increase in international revenue in the first half of 2026, significantly expanding its footprint to over 70 countries. Notably, LifeTech's international revenue reached nearly RMB 400 million in 2025, with an annual growth of 14.4%, showcasing its market prowess outside Mainland China.

Leadership Insights for Future Growth

Dr. Jonathon Zhong Zhao, Chairman of Zylox-Tonbridge, articulated an ambitious vision for the partnership: "This strategic investment marks an important milestone in our ambition to build a leading integrated vascular and structural heart intervention platform in China. By combining our strengths, we aim to create new opportunities for long-term growth."

Concurred Mr. Zhenfu Li, CEO of GL Capital, emphasizing their commitment to empowering the Chinese healthcare landscape: "We see significant potential in China's vascular intervention market. This investment brings together complementary resources that can revolutionize our collaborative goals and support our global growth ambitions."

LifeTech's Founder, Mr. Yuehui Xie, echoed these sentiments, emphasizing this phase as a new chapter, anticipating collaborative advancements that will fortify LifeTech's competitive stance in the market.

In Conclusion: A Bright Future Ahead

As these innovative companies prepare to embark on this exciting venture together, the anticipated results could significantly transform the medical technology landscape, particularly in vascular interventions. The synergies derived from this partnership promise advanced solutions that will benefit healthcare providers and patients alike, marking a new era in medical technology in China.